Initial Trials of Anti-CD80 Monoclonal Antibody (Galiximab) Therapy for Patients with Relapsed or Refractory Follicular Lymphoma
- 1 March 2003
- journal article
- Published by Elsevier in Clinical Lymphoma
- Vol. 3 (4), 257-259
- https://doi.org/10.3816/clm.2003.n.008
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyJournal of the American Academy of Dermatology, 2002
- Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell LymphomaJournal of Biological Chemistry, 2002
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Costimulatory regulation of T cell functionCurrent Opinion in Cell Biology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Localization in situ of costimulatory molecules and cytokines in B‐cell non‐Hodgkin’s lymphomaImmunology, 1998
- In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell ProliferationBlood, 1997
- Malignant B lymphocytes from non‐Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co‐stimulatory molecules CD80 (B7‐1) and CD86 (B7‐2) in stimulation by tumor cellsEuropean Journal of Immunology, 1995
- “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4Nature Biotechnology, 1992